Form 4: CRISPR Therapeutics AG: Chief Medical Officer Naimish Patel Reports Stock Option and Restricted Stock Unit Grants

Naimish Patel, Chief Medical Officer of CRISPR Therapeutics AG, reports the grant of stock options and restricted stock units.

Summary

• On March 14, 2025, Naimish Patel, the Chief Medical Officer of CRISPR Therapeutics AG, was granted stock options for 46,667 common shares at an exercise price of $42.12.
• These options vest in 48 equal monthly installments starting April 14, 2025.
• Patel also received 32,500 restricted stock units (RSUs), each representing a contingent right to receive one share of CRSP common stock.
• The RSUs vest in four equal installments on March 14 of 2026, 2027, 2028, and 2029.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to slightly positive.

Positives

• The grant of stock options and RSUs to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the executive.

Industry Context

Stock option and RSU grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like CRISPR Therapeutics.
• Comparable companies such as Intellia Therapeutics and Editas Medicine also utilize stock options and RSUs to incentivize their leadership teams.
• The vesting schedules described are typical for executive compensation packages in the biotech industry, designed to align executive interests with long-term shareholder value.

Stakeholder Impact

• The grants incentivize the Chief Medical Officer to drive long-term value for shareholders.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates